Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.
Pharvaris N.V. (PHVS) is a pioneering, clinical-stage biopharmaceutical company dedicated to developing novel, oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) and other related conditions. With a strategic focus on unmet medical needs in rare diseases, Pharvaris aims to provide safer, more effective, and easier-to-administer alternatives to currently available injectable therapies.
Core Business and Expertise
Pharvaris is spearheaded by a team with profound expertise in HAE, including the discovery and approval of the HAE treatment icatibant. The company leverages this foundation to develop small, potent molecules targeting the bradykinin B2 receptor—a clinically validated therapeutic target. By inhibiting bradykinin signaling at this receptor, Pharvaris' lead candidate, deucrictibant, offers potential for both acute and prophylactic treatment of HAE and other bradykinin-mediated diseases.
Current Projects and Achievements
- Pharvaris has made significant progress in its clinical development programs. Notably, the U.S. FDA has lifted the clinical hold on deucrictibant, allowing the continuation of global development, including Phase 2 and Phase 3 trials.
- The company's Phase 2 CHAPTER-1 study demonstrated positive top-line data for deucrictibant in preventing HAE attacks, with significant reductions in attack rates at both 20 mg/day and 40 mg/day doses.
- Deucrictibant is being developed in two formulations: a rapid-onset capsule for acute treatment and an extended-release tablet for long-term prophylaxis.
Future Outlook
Pharvaris is preparing for the global Phase 3 CHAPTER-3 study and continues to engage with regulatory authorities to align on study designs. The company is also expanding its research into other bradykinin-mediated conditions, aiming to broaden its therapeutic portfolio.
Financial Condition and Market Presence
Strong financial performance and strategic investor support underscore Pharvaris’ potential. The company’s financial health allows it to fund ongoing and future clinical trials while building infrastructure for the anticipated launch of deucrictibant. Pharvaris is committed to operating transparently, with regular updates provided to its stakeholders through its website and regulatory filings.
With a clear mission to transform the treatment landscape for rare diseases, Pharvaris stands out for its innovative approach and dedication to improving patient outcomes.
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), has announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas from May 10-12, 2022. The company's presentation is scheduled for May 12, 2022, at 10:00 AM PDT (7:00 PM CEST). A live webcast will be accessible on its website, with a replay available for 30 days post-event.
Pharvaris (Nasdaq: PHVS), a clinical-stage company specializing in oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), announced its participation in two investor conferences in April 2022. The 21st Annual Needham Virtual Healthcare Conference will take place on April 11, 2022, at 2:45 PM CEST, while the Kempen 14th Life Sciences Conference is scheduled for April 21, 2022, at 3:00 PM CEST in Amsterdam. Investors can access webcasts of the presentations on the company's website, with replays available for 30 days post-event.
Pharvaris (PHVS) reported significant advancements in its clinical development, including the successful Phase 1 study of PHVS719, confirming its suitability for once-daily dosing. The FDA granted orphan drug designation to PHA121, enhancing its potential market position. Ongoing Phase 2 trials, RAPIDe-1 and CHAPTER-1, target on-demand and prophylactic treatment of hereditary angioedema (HAE), with top-line data expected in 4Q22. The company maintains a strong financial position with €209.4 million in cash, providing a runway into 1Q24.
Pharvaris has released pharmacological data on its novel bradykinin B2 receptor antagonist, PHA121. This compound demonstrates a 20-fold higher potency than icatibant, the only approved injectable B2 antagonist, while offering improved intrinsic clearance and oral bioavailability. The early clinical data indicates rapid absorption and favorable pharmacokinetics in healthy participants. Pharvaris aims to provide an oral treatment for hereditary angioedema (HAE), showcasing PHA121 as the most potent small-molecule antagonist in its category.
Pharvaris (Nasdaq: PHVS) announced participation in three investor conferences in March 2022. The events include:
- BioCapital Europe 2022 on March 10, 2022, at 3:00 PM CET in Amsterdam.
- Oppenheimer 32nd Annual Healthcare Conference via webcast on March 15, 2022, at 8:00 AM ET.
- SVB Leerink Mountain Meeting on March 22, 2022, at 9:30 AM MT in Jackson Hole, Wyoming.
Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference, occurring virtually from February 14–18, 2022. The fireside chat is set for February 16 at 4:40 PM CEST (10:40 AM EST). A live audio webcast will be accessible on the Investors section of their website, with a replay available for 30 days post-event. Pharvaris focuses on developing oral bradykinin-B2-receptor antagonists targeting hereditary angioedema and aims to provide alternatives to existing injected therapies.
Pharvaris (Nasdaq: PHVS) announced the appointment of Dr. Anne Marie de Jonge Schuermans to its board of directors, replacing Rémi Droller, effective December 22, 2021. Dr. de Jonge Schuermans, with extensive experience in biotech and pharmaceutical operations, will support Pharvaris as it prepares for commercialization of its oral bradykinin-B2-receptor antagonists aimed at treating hereditary angioedema (HAE). The company anticipates a clinical data readout from Phase 2 trials within the next year, marking a pivotal step in its development strategy.
Pharvaris (Nasdaq: PHVS) has appointed Dr. Elisabeth Björk to its board of directors, effective December 1, 2021, to strengthen its leadership ahead of anticipated Phase 2 clinical data releases for hereditary angioedema (HAE) treatments. Dr. Björk, a seasoned expert in drug development at AstraZeneca, is set to replace Martijn Kleijwegt, who stepped down to focus on new investments. This leadership change aims to enhance Pharvaris’s capabilities as it prepares for commercialization of its bradykinin-B2-receptor antagonists candidates, PHVS416 and PHVS719, in the upcoming years.
Pharvaris (Nasdaq: PHVS) continues its robust clinical development with two Phase 2 studies for PHVS416 aimed at treating hereditary angioedema (HAE). The RAPIDe-1 study for on-demand treatment is progressing, while the CHAPTER-1 study for prophylactic treatment is now recruiting patients. Additionally, a Phase 1 pharmacokinetics study for PHVS719 is set to begin this month. Financially, Pharvaris reported cash and equivalents of €218.6 million as of September 30, 2021, marking a significant increase from €98.6 million at year-end 2020. However, R&D expenses rose to €9.0 million, and the quarterly loss was €9.1 million.
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on novel oral bradykinin-B2-receptor antagonists, announced its participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. Live audio webcasts will be available on their website, with replays for 30 days following each event.
FAQ
What is the current stock price of Pharvaris N.V. (PHVS)?
What is the market cap of Pharvaris N.V. (PHVS)?
What is Pharvaris N.V. focused on?
What is deucrictibant?
What recent achievements has Pharvaris made?
What clinical trials are ongoing at Pharvaris?
What makes deucrictibant unique?
How is Pharvaris positioned financially?
What is the significance of Pharvaris' focus on oral therapies?
What are Pharvaris' future plans?
Who leads Pharvaris?
Where can I find more information about Pharvaris?
